Profile data is unavailable for this security.
About the company
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastroenterology and dermatology. It develops and manufactures products, which are distributed globally. The Company’s development pipeline is focused on Bowel Diseases, Colon Infections and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Its products include Lialda/Mezavant/Mesavancol and Uceri/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which develops for the treatment of travelers’ diarrhoea (TD), Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy; and Winlevi, which develops for the treatment of acne.
- Revenue in CHF (TTM)75.84m
- Net income in CHF34.24m
- Incorporated--
- Employees292.00
- LocationCosmo Pharmaceuticals NVRiverside II, Sir John Rogerson's QuayDUBLIN IrelandIRL
- Phone+353 18170370
- Websitehttp://www.cosmopharma.com/
More ▼
Mergers & acquisitions
| Acquired company | COPN:SWX since announced | Transaction value |
|---|---|---|
| Cassiopea SpA | -33.08% | 228.73m |
Data delayed at least 15 minutes, as of Aug 17 2022 16:31 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calliditas Therapeutics AB | 25.62m | -53.42m | 583.79m | 71.00 | -- | 6.63 | -- | 23.02 | -11.38 | -11.38 | 5.47 | 16.38 | 0.2077 | 1.08 | 88.21 | 4,228,500.00 | -43.88 | -31.46 | -49.82 | -34.68 | 17.60 | -- | -211.31 | -288.51 | 5.36 | -88.31 | 0.1976 | -- | 26,141.08 | -- | -15.41 | -- | 145.12 | -- |
| Pharming Group N.V. | 189.96m | 19.57m | 621.29m | 321.00 | 35.34 | 3.36 | 16.65 | 3.31 | 0.0283 | 0.0283 | 0.2814 | 0.2972 | 0.5036 | 0.7075 | 5.76 | 612,706.80 | 5.19 | 2.73 | 5.90 | 3.87 | 89.84 | 87.36 | 10.30 | 4.39 | 4.53 | -- | 0.4273 | -- | -6.27 | 62.49 | -57.62 | -- | 66.17 | -- |
| Pharmanutra SpA | 70.23m | 14.24m | 640.49m | 64.00 | 45.32 | 14.25 | 43.44 | 9.19 | 1.52 | 1.52 | 7.51 | 4.84 | 1.11 | 0.8189 | 4.13 | 1,172,839.00 | 22.60 | 23.06 | 29.73 | 32.33 | 97.04 | 95.39 | 20.28 | 19.37 | 2.93 | -- | 0.113 | 50.80 | 20.66 | 15.75 | -2.14 | 29.03 | 18.07 | -- |
| Surgical Science Sweden AB | 44.86m | 9.29m | 681.80m | 224.00 | 58.85 | 2.07 | 53.66 | 15.56 | 2.54 | 2.54 | 11.73 | 72.32 | 0.1935 | 2.22 | 6.80 | 2,338,335.00 | 4.01 | 3.41 | 4.27 | 3.67 | 69.07 | 78.80 | 20.71 | 15.42 | 2.18 | -- | 0.0432 | 0.00 | 249.98 | 47.90 | 452.66 | 92.43 | 4.25 | -- |
| Ergomed PLC | 136.18m | 14.56m | 693.82m | 1.26k | 49.58 | 9.10 | 35.00 | 5.23 | 0.2505 | 0.2505 | 2.34 | 1.36 | 1.20 | -- | 5.06 | 94,486.85 | 12.78 | 4.27 | 19.60 | 6.13 | 40.78 | 41.18 | 10.69 | 3.85 | -- | 53.75 | 0.0383 | 0.00 | 37.26 | 24.76 | 30.90 | -- | -2.38 | -- |
| Puretech Health PLC | 16.33m | -56.89m | 737.78m | 95.00 | -- | 1.32 | -- | 44.45 | -0.1734 | -0.1734 | 0.0496 | 1.69 | 0.018 | -- | 6.07 | 149,719.80 | -6.48 | 4.86 | -8.07 | 6.24 | -- | -- | -360.65 | 260.53 | -- | -- | 0.0818 | 0.00 | 47.76 | 31.45 | -1,111.83 | -- | 9.02 | -- |
| Zealand Pharma A/S | 33.74m | -124.27m | 740.11m | 345.00 | -- | 7.46 | -- | 21.94 | -22.16 | -23.12 | 6.02 | 16.42 | 0.1297 | 1.99 | 3.89 | 731,901.40 | -47.76 | -31.81 | -57.58 | -37.07 | 62.29 | -- | -368.33 | -247.19 | 4.78 | -- | 0.5268 | -- | -17.19 | 4.85 | -20.24 | -- | 53.47 | -- |
| MorphoSys AG | 188.43m | -822.30m | 760.43m | 648.00 | -- | -- | -- | 3.93 | -24.93 | -24.93 | 5.71 | -0.804 | 0.0955 | 2.22 | 1.79 | 266,525.00 | -41.67 | -13.97 | -47.78 | -15.73 | 78.40 | -- | -436.39 | -89.38 | 2.91 | -4.03 | 1.09 | -- | -45.19 | 29.28 | -625.55 | -- | 55.11 | -- |
| Boiron SA | 439.65m | 27.58m | 804.93m | 2.77k | 28.90 | 1.55 | 19.52 | 1.82 | 1.63 | 1.63 | 25.99 | 30.36 | 0.5864 | 1.50 | 4.89 | 164,391.80 | 3.68 | 5.96 | 4.69 | 7.50 | 71.97 | 76.84 | 6.27 | 8.41 | 2.32 | -- | 0.0232 | 46.86 | -11.37 | -5.82 | 8.95 | -18.15 | -10.06 | -9.90 |
| BioGaia AB | 87.39m | 22.58m | 814.42m | 195.00 | 37.90 | 5.34 | 33.33 | 9.44 | 2.44 | 2.44 | 9.43 | 17.30 | 0.4738 | -- | -- | 5,700,270.00 | 12.24 | 18.70 | 13.32 | 21.27 | 73.01 | 74.18 | 25.84 | 26.20 | -- | 351.31 | 0.00 | 75.30 | 5.09 | 7.99 | 9.20 | 4.22 | 38.51 | -0.6484 |
| Cosmo Pharmaceuticals NV | 75.84m | 34.24m | 891.20m | 292.00 | 27.58 | 1.84 | 18.90 | 11.69 | 1.83 | 1.83 | 4.22 | 27.39 | 0.1177 | 2.92 | 3.81 | 261,524.70 | 5.32 | -2.09 | 5.51 | -2.16 | 53.43 | 59.64 | 45.17 | -19.05 | 10.81 | -- | 0.268 | -- | 6.77 | -0.7776 | 374.29 | 2.30 | -14.33 | -- |
| Eckert&Ziegler Strahlen und Mdzntchnk AG | 179.81m | 26.40m | 915.69m | 930.00 | 35.05 | 4.90 | 26.30 | 5.24 | 1.31 | 1.31 | 8.95 | 9.41 | 0.5561 | 2.43 | 5.25 | 214,974.60 | 8.22 | 8.38 | 9.82 | 10.13 | 50.18 | 47.84 | 14.79 | 12.77 | 2.39 | -- | 0.1177 | 35.57 | 2.44 | 5.52 | 62.20 | 27.08 | 40.17 | 24.82 |
| Fagron NV | 604.40m | 67.04m | 979.93m | 3.06k | 14.35 | 2.67 | 9.94 | 1.59 | 0.9508 | 0.9508 | 8.57 | 5.10 | 0.7136 | 3.50 | 10.55 | 204,438.40 | 7.95 | 7.30 | 9.93 | 9.98 | 42.18 | 44.05 | 11.14 | 10.41 | 1.23 | 14.06 | 0.5278 | 12.97 | 3.21 | 6.35 | 2.35 | -- | 7.01 | -- |
| Nykode Therapeutics ASA | 32.45m | -9.29m | 1.02bn | 128.00 | -- | 5.79 | -- | 31.94 | -0.3771 | -0.3771 | 1.16 | 6.28 | 0.1433 | -- | 3.82 | 3,240,462.00 | -4.10 | 25.30 | -4.53 | 27.55 | -- | -- | -28.64 | 46.19 | -- | -- | 0.0357 | -- | -84.20 | 311.05 | -106.29 | -- | 157.24 | -- |
| Swedencare AB (publ) | 122.12m | 9.02m | 1.10bn | 513.00 | 123.90 | 1.65 | 41.16 | 9.05 | 0.6147 | 0.6147 | 9.68 | 46.12 | 0.2073 | 2.30 | 8.51 | 4,751,254.00 | 1.53 | 4.78 | 1.60 | 5.07 | 51.67 | 57.82 | 7.39 | 11.94 | 1.18 | -757.78 | 0.1812 | 32.49 | 221.77 | 70.46 | 63.76 | 41.06 | -- | -- |
| Valneva SE | 334.87m | -69.31m | 1.15bn | 722.00 | -- | 7.38 | 56.38 | 3.44 | -0.7206 | -0.7206 | 3.42 | 1.38 | 0.513 | 1.58 | 13.82 | 480,218.80 | -10.62 | -8.98 | -21.48 | -12.92 | 46.03 | 53.98 | -20.70 | -18.41 | 1.12 | -2.63 | 0.4377 | -- | 215.52 | 29.91 | -14.03 | -- | 90.83 | -- |
Data as of Aug 17 2022. Currency figures normalised to Cosmo Pharmaceuticals NV's reporting currency: Swiss Franc CHF
9.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 08 Mar 2022 | 524.55k | 2.99% |
| The Vanguard Group, Inc.as of 05 Aug 2022 | 263.03k | 1.50% |
| Baillie Gifford & Co.as of 30 Jun 2022 | 237.07k | 1.35% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 163.76k | 0.93% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Jul 2022 | 125.54k | 0.72% |
| BlackRock Fund Advisorsas of 03 Aug 2022 | 114.12k | 0.65% |
| Sp-Fund Management Co. Ltd.as of 29 Jul 2022 | 93.60k | 0.53% |
| AMG Fondsverwaltung AGas of 30 Jun 2022 | 60.54k | 0.35% |
| Healthinvest Partners ABas of 30 Jun 2022 | 60.00k | 0.34% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2020 | 57.54k | 0.33% |
More ▼
Data from 31 Dec 2021 - 29 Jul 2022Source: FactSet Research Systems Inc.
